within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AA18_PolymyxinB;

model PolymyxinB
  extends Pharmacolibrary.Drugs.ATC.S.S01AA18;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01AA18</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Polymyxin B is an antibiotic primarily used to treat severe Gram-negative bacterial infections, including those caused by multidrug-resistant bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. It is typically administered intravenously or topically and is reserved for serious infections due to potential nephrotoxicity and neurotoxicity. Polymyxin B is approved and used in clinical practice, especially for life-threatening infections where alternative treatments are not effective.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult critically ill patients treated with IV polymyxin B, based on population pharmacokinetic analysis.</p><h4>References</h4><ol><li><p>Tran, TB, et al., &amp; Li, J (2016). Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?. <i>International journal of antimicrobial agents</i> 48(6) 592–597. DOI:<a href=\"https://doi.org/10.1016/j.ijantimicag.2016.09.010\">10.1016/j.ijantimicag.2016.09.010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27793510/\">https://pubmed.ncbi.nlm.nih.gov/27793510</a></p></li><li><p>Kubin, CJ, et al., &amp; Yin, MT (2018). Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples. <i>Antimicrobial agents and chemotherapy</i> 62(3) –. DOI:<a href=\"https://doi.org/10.1128/AAC.01493-17\">10.1128/AAC.01493-17</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29311066/\">https://pubmed.ncbi.nlm.nih.gov/29311066</a></p></li><li><p>Yu, Z, et al., &amp; Yu, Y (2025). Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant gram-negative bacterial infections: a prospective observational multicenter study. <i>Antimicrobial agents and chemotherapy</i> 69(4) e0185924–None. DOI:<a href=\"https://doi.org/10.1128/aac.01859-24\">10.1128/aac.01859-24</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40047414/\">https://pubmed.ncbi.nlm.nih.gov/40047414</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end PolymyxinB;
